MedTrace Logo

Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer

NCT04724460 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2025-03-11

No results posted yet for this study

Summary

The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmonary embolism patients. The major secondary purpose of this study is to investigate whether home treatment of cancer-associated low-risk pulmonary embolism patients with rivaroxaban is feasible, effective, and safe through an observational management study.

Conditions

  • Venous Thrombosis
  • Neoplasms
  • Anticoagulants

Interventions

DRUG

Long DOAC

Administration of Rivaroxaban for 18 months

DRUG

Short DOAC

Administration of Rivaroxaban for 6 months

Sponsors & Collaborators

  • Bayer Yakuhin, Ltd.

    collaborator INDUSTRY

  • Takeshi Morimoto

    lead OTHER

Principal Investigators

  • Takeshi Kimura, MD, PhD · Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2024-09-27
Completion
2024-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04724460 on ClinicalTrials.gov